Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT04844580 Recruiting - Covid19 Clinical Trials

A Clinical Study Evaluating Inhaled Aviptadil on COVID-19

Start date: March 10, 2021
Phase: Phase 2
Study type: Interventional

This study is a multicenter, prospective, placebo-controlled, comparative, randomized, double-blind local phase II clinical trial. Duration of study is 18 months. In the study, patients will be randomized in a ratio of 1: 1 into two arms, standard medical therapy + placebo versus standard medical therapy + inhaled Aviptadil arms. Randomization will be carried out by the block randomization method. In the event that patients need intensive care in the study, the patients will be taken into intensive care unit and excluded from the study and their treatment will be continued in the intensive care unit as deemed appropriate by the physician and it is foreseen that inhaled Aviptadil will be used for a period of minimum 7 and maximum 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. This study includes 8 visits, consisting of a total of 7 physical visits and 1 phone follow-up visit. The study period will be 6 months for each patient. Patient recruitment is planned to take 12 months. Study centers will be asked to use investigational products for their patients who sign the informed consent form for 12 months. The study population will consist of patients 18 years of age and older with COVID-19 pulmonary involvement and hospitalized patients.

NCT ID: NCT04844567 Recruiting - Covid19 Clinical Trials

Virtual Reality Intervention to Alleviate Breathlessness (COVID-19)

Start date: November 26, 2020
Phase: N/A
Study type: Interventional

This study evaluates the feasibility and limited efficacy of a Virtual Reality (VR) intervention to alleviate symptoms of perceived breathlessness and dyspnea in individuals recovering from severe COVID-19 pneumonia.

NCT ID: NCT04843722 Recruiting - Covid19 Clinical Trials

COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

Start date: April 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19. This clinical trial is designed to assess the safety, efficacy, reactogenicity, and immunogenicity of hAd5-S-Fusion+N-ETSD formulated for subcutaneous, sublingual, and oral (capsule) administration.

NCT ID: NCT04842708 Recruiting - Covid19 Clinical Trials

Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis

Start date: December 24, 2020
Phase: N/A
Study type: Interventional

The objective of this study will be to evaluate the effect of vaccination on breath VOC content. By capturing and analyzing the breath of anti-COVID-19 vaccinated subjects during the period of antibody production, the investigators will determine and quantify all the compounds associated with the body reaction to the COVID-19 antigen.

NCT ID: NCT04842292 Recruiting - Covid19 Clinical Trials

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Start date: April 12, 2021
Phase: Phase 2
Study type: Interventional

The objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in COVID-19 and prevent harmful effects possible with systemic anticoagulation.

NCT ID: NCT04841707 Recruiting - Covid19 Clinical Trials

Total-Body Parametric 18F-FDG PET of COVID-19

Start date: April 22, 2021
Phase: N/A
Study type: Interventional

The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.

NCT ID: NCT04840940 Recruiting - Covid19 Clinical Trials

Presepsin Biomarker for Ventilator-associated Pneumonia Diagnosis in COVID-19 Patients

Start date: December 21, 2020
Study type: Observational

This study is observational and double blind. It evaluates the validity of presepsin (a serum biomarker of bacterial infections) as early biomarker of Ventilator Associated Pneumonia. It will be measured at day 0 (ICU admission) and every 48 hours in every patient with Sars-Cov 2 interstitial pneumonia requiring invasive mechanical ventilation (see inclusion ad exclusion criteria) until Day 30, ICU discharge or ICU death. There will be no change in clinical practice and in pneumonia diagnosis. We will examine how the elevation of presepsin level could be an early marker of ventilator associated pneumonia or a marker of bacterial pneumonia at ICU admission, before the micriobiological results or clinical diagnosis.

NCT ID: NCT04840459 Recruiting - Covid19 Clinical Trials

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Start date: November 20, 2020
Phase: Phase 2
Study type: Interventional

No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high risk patients. Recognizing this limitation and urgency of finding a treatment for COVID-19, the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergencyuse of the unapproved product bamlanivimab or casirivimab + imdevimab for the treatment of mild to moderate coronavirus disease 2019 (COVID19) in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

NCT ID: NCT04839146 Recruiting - Covid19 Clinical Trials

Safety and Tolerability of ABNCoV2

Start date: March 11, 2021
Phase: Phase 1
Study type: Interventional

This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the immunogenicity-tolerability ratio 14 days following first vaccination with ABNCoV2.

NCT ID: NCT04839107 Recruiting - Covid19 Clinical Trials

Institutional Registry on Outpatient and Hospitalized COVID-infected Patients

Start date: April 14, 2020
Study type: Observational [Patient Registry]

Creation of an Institutional Registry system for patients with confirmed COVID-19 infection with the collection of epidemiological data, risk factors, diagnosis, prognoses, treatment, follow-up and survival.